Study on association of polymorphism of CYP450 2D6 with head and neck cancer and treatment response in patients receiving neoadjuvant chemotherapy paclitaxel, cisplatin, 5fu (TPF) followed by chemoradiation

Divyesh Kumar, Mohan Chand Pant, Devendra Parmar, Sudhir Singh, Madanlal Brahmabhatt


Background: Aims of this study were to study the association of genetic polymorphism in CYP450 2D6 in patients of locally advanced head and neck cancer, and try to assess a correlation between this polymorphism & response to treatment. Need of the study was to find out a possible genetic level explanation for the different response achieved in patients with similar histopathology, stage, exposure to carcinogen & ethnicity undergoing similar treatment.

Methods: A study comprising of 150 patients & 150 controls was done to analyze the association between polymorphs of CYP450 2D6 with head & neck cancer and treatment response (TPFàCTRT). Two cycles of TPF (paclitaxel-175mg/m2 D1, cisplatin 35mg/m2 D2-D3 and 5Fu 1gm/m2 D1-D3) were given followed by radiotherapy with concurrent cisplatin (40 mg/m2).The response to the treatment was assessed clinically, radiologically & by  laryngoscopy-post treatment. Genotyping of the blood samples was done. Analysis of the association between genetic polymorphisms and risk of HNSCC was estimated by calculating crude odds ratio (OR). A P value of <0.05 was considered statistically significant. The statistical analysis was performed with the SPSS software package (version 11.0 for Windows; SPSS Chicago, IL).

Results: Patients with CYP 2D6*1 showed good response to the therapy given, while CYP 2D6*4 and *10 were poor responders.

Conclusion: There is a strong association of polymorphs of CYP 2D6 with occurrence of head and neck cancer. Response to treatment (TPFàCT-RT) is polymorph graded. Our study thus provides an insight in to the concept of “Right therapy to the right patient”.



Polymorphism, CYP450 2D6, Chemoradiation

Full Text:



Sankaranarayanan R, Masuyer E, Swami Nathan R, Ferlay J, Whelan S. Head and neck cancer: a global perspective on epidemiology and survival. Anticancer Res. 1998;18:4779-86.

Wright AJ, Ogden GR. Possible mechanisms by which alcohol may influence the development of oral cancer: a review. Oral Oncol. 1998;34:441-7.

Vaca CE, Nilsson JA, Fang JL. Grafatrom RC. Formation of DNA adducts in human buccal epithelial cells exposed to acetaldehyde and methylglyoxal in vitro. Chem Biol Interact. 1998;108:197-208.

Molina PE, Hoek JB, Nelson S et al. Mechanisms of alcohol induced tissue injury. Alcohol Clin Exp Res. 2003;27:563-75.

Lieber CS. Relationship between nutrition, alcohol use and liver disease. Alcohol Res Health 2003;27:220-31.

Leo MA, Lieber CS. Alcohol, vitamin A, and beta-carotene: adverse interactions, including hepatotoxicity and carcinogenicity. Am J Clin Nutr 1999;69:1071-85.

Cook RT. Alcohol abuse, alcoholism, and damage to the immune system: review. Alcohol Clin Exp Res. 1998;22:1927-42.

Sobti RC, Onsory K, Al-Badran AI, Kaur P, Watanabe M, Krishan A, Mohan H. CYP 17, SRD 5A2, CYP 1B1, and CYP 2D6 gene polymorphisms with prostate cancer risk in North Indian population. DNA Cell Biol. 2006 May;25(5):287-94.

Gajecka M, Rydzanicz M, Jaskula-Sztul R, Kujawski M, Szyfter W, Szyfter K. CYP 1A1, CYP 2D6, CYP 2E1, NAT2, GSTM1 and GSTT1 polymorphisms or their combinations are associated with the increased risk of the laryngeal squamous cell carcinoma. Mutat Res. 2005 Jul;574(1-2):112-23.

Zienolddiny S, Campa D, Lind H, Ryberg D, Skaug V, Stangeland LB, Canzian F, Haugen A. A comprehensive analysis of phase I and phase II metabolism gene polymorphisms and risk of non-small cell lung cancer in smokers. Carcinogen. 2008 Jun;29(6):1164-9.

Abdel-Rahman SZ, Anwar WA, Abdel-Aal WE, Ghoneim MA, Au WW. The CYP 2D6 extensive metabolizer genotype is associated with increased risk for bladder cancer. Cancer Lett. 1997 Oct;119(1):115-22.

Leonor Gomes. CYP 2D6 genetic polymorphisms are associated with susceptibility to pituitary tumors. Acta Med Port. 2005;18:339-44.

Lemos MC, Cabrita FJ, Silva HA, Vivan M, Placido F, Regateiro FJ. Genetic polymorphism of CYP 2D6, GSTM1 and NAT2 and susceptibility to haematological neoplasia. Carcinogen. 1999;20:1225-9.

Ladona MG, Ablidua RE Ladero JM, Roman JM, Plaza MA, Agundez JAG ,Munoz JJ, Benitz J. CYP 2D6 genotypes in Spanish women with breast cancer. Cancer Letters. 1996;99:23-8. Blot WJ, McLaughlin JK, Winn DM. Smoking and drinking in relation to oral and pharyngeal cancer. Cancer Res. 1988;48:3282-7.

De Jong MM, Nolte IM, Te Meerman GJ, Van der Graaf WT, Oosterwijk JC, Kleibeuker JH, Schaapveld M, de Vries EG. Genes other than BRCA1 and BRCA2 involved in breast cancer

Bouchardy C, Benhamon S, Dayer P. The effect of tobacco on lung cancer risk depends on CYP 2D6 activity. Cancer Res. 1996;56:251-3.